Product image of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) supplied by GNH India

Mircera

Active Ingredient:
Methoxy Polyethylene Glycol-Epoetin Beta
Origin:
EU

Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)

Methoxy polyethylene glycol‑epoetin beta, the active ingredient in Mircera, is an erythropoiesis‑stimulating agent presented as a solution for injection for intravenous and subcutaneous use. It treats anemia in chronic kidney disease patients, both on dialysis and not on dialysis.

GNH India supplies Mircera as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Roche Registration Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mircera is used to manage anemia associated with chronic kidney disease, an erythropoiesis‑stimulating therapy.

  • Anemia in chronic kidney disease patients on dialysis: improves hemoglobin levels and reduces the need for blood transfusions.
  • Anemia in chronic kidney disease patients not on dialysis: supports red blood cell production and helps maintain target hemoglobin.
  • Anemia related to renal failure: assists in achieving stable hemoglobin concentrations.

How It Works

  • Methoxy polyethylene glycol‑epoetin beta is a long‑acting erythropoietin analog that binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow. This binding activates the JAK2/STAT5 signaling pathway, stimulating proliferation and differentiation of red blood cell precursors, thereby increasing red blood cell mass and hemoglobin concentration. The polyethylene glycol moiety extends its circulating half‑life, allowing less frequent dosing compared with conventional epoetin products.

Side Effects

Mircera may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate headache reported.
  • Hypertension: increase in blood pressure observed.
  • Injection site reactions: pain, erythema, or swelling at the site.
  • Flu‑like symptoms: fever, chills, or fatigue.

Serious or Rare Side Effects

  • Thromboembolic events: risk of blood clots including deep vein thrombosis or pulmonary embolism.
  • Pure red cell aplasia: rare immune‑mediated loss of erythropoiesis.
  • Severe hypertension or hypertensive crisis: sudden, marked elevation in blood pressure.

Precautions & Warnings

When using Mircera, several precautions should be observed to ensure safety and efficacy.

  • Monitor hemoglobin: adjust dose to maintain target levels and avoid excessive rise.
  • Blood pressure monitoring: check regularly due to risk of hypertension.
  • Iron status: ensure adequate iron stores before and during therapy.
  • Cardiovascular disease: use cautiously in patients with active cardiovascular conditions.
  • Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mircera can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Antiplatelet agents: increased risk of hypertension and thrombotic events.
  • Chemotherapy agents causing myelosuppression: additive risk of anemia.
  • ACE inhibitors or ARBs: may blunt erythropoietic response.

Moderate Interactions (Monitor Closely)

  • Iron supplements: may improve response, monitor iron parameters.
  • Vitamin B12 or folic acid deficiency: correct deficiencies to optimize efficacy.
  • Other erythropoiesis‑stimulating agents: avoid concurrent use to prevent overdose.

Frequently Asked Questions

Mircera is indicated for the treatment of anemia in patients with chronic kidney disease, both those receiving dialysis and those who are not. It helps raise and maintain hemoglobin levels, reducing the need for blood transfusions in this patient population.

Methoxy polyethylene glycol‑epoetin beta is a synthetic form of erythropoietin that binds to erythropoietin receptors on bone‑marrow progenitor cells. This activates intracellular signaling pathways that stimulate the proliferation and maturation of red blood cell precursors, leading to increased red blood cell production and higher hemoglobin.

The dose of Mircera is individualized and determined by the prescribing clinician based on the patient’s hemoglobin level, weight, dialysis status, and response to therapy. The prescriber will set the appropriate dosing schedule and adjustments.

The safety of Mircera in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Mircera, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Mircera is a long‑acting, pegylated erythropoietin analog, allowing less frequent dosing compared with shorter‑acting agents such as epoetin alfa. Its extended half‑life can improve patient convenience, but efficacy and safety profiles are comparable, and choice depends on clinical judgment, dosing preferences, and individual patient response.

Mircera should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Mircera is supplied as a sterile solution for injection and can be given either intravenously or subcutaneously. Administration is performed by a qualified healthcare professional following aseptic technique, with the dose and frequency set by the prescribing clinician.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, pure red cell aplasia, and severe hypertension or hypertensive crisis. Patients should be monitored closely for signs of clotting, sudden blood pressure spikes, and any unexpected drop in red blood cell production.

Mircera should be avoided in patients with known hypersensitivity to methoxy polyethylene glycol‑epoetin beta or any of its excipients, in those with uncontrolled hypertension, and in individuals with active malignancies where erythropoiesis‑stimulating agents may accelerate tumor progression. Contra‑indications are determined by the treating physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methoxy Polyethylene Glycol-Epoetin Beta

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT